2023年2月7日

披露:Sandborn報告與AbbVie金融關係,Abivax, AdMIRx, Alfasigma, Alimentiv, Alivio療法,Allakos,安進,應用分子運輸、舞台製藥、博士倫健康,BeiGene,貝拉特裏克斯製藥、勃林格殷格翰的發言,波士頓製藥、百時美施貴寶公司,Celgene公司,Celltrion,多孔性,Cosmo製藥、Escalier生物科學,Equillium, Forbion,基因泰克,吉裏德科學Glenmark製藥、輕飄飄的生物,葛蘭素史克,Immunic(至關重要的療法),索引製藥、完整的療法,詹森,Kyverna療法,藍多士生物製藥,莉莉,Oppilan醫藥,大塚,Pandion療法,輝瑞公司Progenity,普羅米修斯生物科學,普羅米修斯實驗室,主角療法,Provention生物Reistone生物製藥,賽裏斯療法,上海醫藥Biotherapeutics,夏爾,海岸線生物科學,崇高療法,Surrozen,武田,治療先鋒生物製藥,西蒂斯製藥、Tillotts製藥,UCB,韋丹塔生物科學,Ventyx生物科學,Vimalan生物科學,Vivelix製藥、Vivreon生物科學和新西蘭製藥公司。請參閱研究對於所有其他作者的相關財務信息披露。主題添加到郵件提醒收到一封電子郵件在發布新文章時請提供您的電子郵件地址來接收電子郵件當張貼新文章。請稍後再試。如果你繼續這個問題請聯係customerservice@slackinc.com。回到Healio Ritlecitinib梅奧和brepocitinib誘導療法更有效地減少總得分與安慰劑相比在中度到重度潰瘍性結腸炎患者,根據臨床胃腸病學和肝髒病學中的數據。“當前批準的小分子(Janus激酶(激酶)抑製劑治療潰瘍性結腸炎包括tofacitinib filgotinib upadacitinib。激酶抑製劑選擇性配置文件可能不同影響潰瘍性結腸炎,選擇性木菠蘿抑製之間的聯係和一種改進的效益/風險尚未闡明,”威廉·j·Sandborn MD,胃腸病學家,聖地亞哥加州大學的醫學教授,和他的同事寫道。”JAK3 Ritlecitinib /酪氨酸激酶表達肝細胞癌家庭抑製劑和brepocitinib, TYK2 / JAK1抑製劑,口服激酶抑製劑在臨床的發展。”“誘導療法ritlecitinib和brepocitinib比安慰劑更有效治療中度到重度潰瘍性結腸炎,接受短期安全概要文件,”威廉·j·Sandborn醫學博士和他的同事寫道。年代ource: Adobe Stock In the VIBRATO phase 2b, double-blind randomized umbrella study, Sandborn and colleagues assessed the efficacy of ritlecitinib and brepocitinib induction therapy in patients aged 18 to 75 years with moderate to severe UC. Of 317 patients included, 150 received ritlecitinib (20 mg, n = 51; 70 mg, n = 49; 200 mg, n = 50), 142 received brepocitinib (10 mg, n = 48; 30 mg, n = 47; 60 mg, n = 47) and 25 received placebo once daily for 8 weeks. The primary endpoint was total Mayo Score (TMS) at week 8. William J. Sandborn At the end of the study period, mean TMS was 7.9 in the placebo group and 5.9, 4 and 3.3 in the 20-mg, 70-mg and 200-mg ritlecitinib groups, respectively; In the 10-mg, 30-mg and 60-mg brepocitinib groups, mean TMSs were 6.1, 5.6 and 4.7, respectively. Placebo-adjusted mean TMSs were –2 (90% CI, –3.2 to –0.9), –3.9 (90% CI, –5 to –2.7) and –4.6 (90% CI, –5.8 to –3.5) points for ritlecitinib groups, respectively, and –1.8 (90% CI, –2.9 to –0.7), –2.3 (90% CI, –3.4 to –1.1) and –3.2 (90% CI, –4.3 to –2.1) points for brepocitinib groups. Further, the estimated placebo-adjusted proportions of patients with modified clinical remission were 13.7%, 32.7% and 36% for ritlecitinib groups and 14.6%, 25.5% and 25.5% for brepocitinib groups, respectively. Treatment-emergent adverse events occurred in 46.1% of patients, including 43.3% in the ritlecitinib group, 47.9% in the brepocitinib group and 52% in the placebo group. Anemia, headache and nasopharyngitis were among the most reported all-cause adverse events. “Induction therapies with ritlecitinib and brepocitinib were more effective than placebo for treatment of moderate to severe ulcerative colitis , with acceptable short-term safety profiles,” Sandborn and colleagues concluded. Read more about